Epigral Ltd shares fell sharply after the company reported a steep 37% year-on-year (YoY) decline in its net profit for the second quarter of FY2025. The company’s consolidated net profit dropped to ₹51.2 crore, compared to ₹81.3 crore in the same period last year.
Revenue also took a hit, slipping 6.2% YoY to ₹587.3 crore, down from ₹626 crore in Q2 FY2024. Operational performance weakened as well, with EBITDA falling 25.6% to ₹132 crore, compared to ₹178 crore a year ago.
The company’s EBITDA margin contracted by 600 basis points, dropping to 22.6% from 28.5% last year, indicating pressure on profitability amid softer pricing and higher input costs.
The disappointing quarterly numbers triggered a sharp sell-off in Epigral’s stock, which tanked over 6% on the BSE following the results announcement.
Disclaimer: This article is for informational purposes only. It is not intended to be investment advice or a recommendation to buy or sell any stock. Readers are advised to consult their financial advisor before making any investment decisions.
